GT Biopharma is trading at $7.20, up 5.95%, as of 9:38 a.m. ET on October 13, 2026; no confirmed company-specific announcement explains the move. - The investor-relations page lists September 15 as the latest press release. - An October 9 filing registered up to 13.5 million shares for potential sale by existing stockholders, not the company; it does not establish the reason for this morning’s rise. - Broader indices are mixed, and available evidence points to no clear market-wide driver.